《Nature,4月3日,COVID-19 in children and altered inflammatory responses》

  • 来源专题:COVID-19科研动态监测
  • 编译者: zhangmin
  • 发布时间:2020-04-04
  • COVID-19 in children and altered inflammatory responses

    Eleanor J. Molloy & Cynthia F. Bearer

    Pediatric Research (2020)

    The COVID-19 pandemic while affecting all age-groups appears to be less severe in children. In this journal we have international contributions relaying experiences from paediatricians across the world. Patients under 18 years only account for 2% of severely affected patients. However children can still be vectors if they are asymptomatic and shedding the virus. Dong et al described a cohort of 2143 children with suspected infection. In 34% infection was confirmed but there was little critical illness and one death. There appeared to be proportionally more severe illness in infants, a result that could have be confounded by concomitant bronchiolitis(1). Chen H et al and others have also shown there is no evidence of vertical transmission in pregnant women (2-6), although this possibility may still exist. Possible reason for this disparity in severity between adults and children may related to differences in receptors in the Renin-angiotensin system (RAS) and altered inflammatory responses to pathogens.

  • 原文来源:https://www.nature.com/articles/s41390-020-0881-y
相关报告
  • 《4月3日_儿童COVID-19及其针对病原体的不同炎症反应》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-04-04
    • 1.时间:2020年4月3日 2.机构或团队:都柏林大学、圣詹姆斯医院、美国彩虹婴儿和儿童医院、凯斯西储大学 3.事件概要: 都柏林大学等机构的科研人员在Pediatric Research上发表文章“COVID-19 in Children and Altered Inflammatory Responses”,探讨了儿童COVID-19与炎症反应改变。 文章指出,虽然影响所有年龄组的COVID-19大流行在儿童中似乎没有那么严重,18岁以下的患者仅占重症患者的2%。但是,如果儿童没有症状并脱落病毒,他们仍然可以成为病毒传播媒介。Dong等描述了2143名疑似感染儿童的队列,34%确诊感染,但危重症很少,有1人死亡。婴儿患病的比例似乎更大,可能与并发的细支气管炎相混淆。Chen H等人还表明,没有证据表明孕妇有垂直传播的证据,尽管这种可能性仍然可能存在。成人和儿童之间严重性差异的可能原因可能与肾素-血管紧张素系统(RAS)受体的差异以及对病原体的炎症反应改变有关。 文章提到,中国正在进行一项临床试验,其中包括接受托珠单抗治疗的严重影响的IL-6升高患者。这项研究已经取得了积极的成果,并显示出迄今有20名患者的症状改善。Tocilizumab靶向IL-6受体,是一种单克隆抗体。它被批准用于巨细胞动脉炎和类风湿关节炎。但是,在诸如青少年免疫性关节炎之类的疾病中,似乎仅靠IL-6阻断不足以控制炎症级联反应,特别是在那些体温低细胞计数和铁蛋白水平较低且肝酶较高的患者中。皮质类固醇可阻止炎症,但世卫组织目前的临时指南建议不要使用皮质类固醇,原因是缺乏有益的证据以及由于免疫抑制和继发性细菌或真菌感染而造成伤害的风险。 由于人体对全身感染有反应,败血症被描述为两个不同的阶段。首先是一个深刻的初期促炎期或细胞因子风暴,然后是一段可能延长的免疫抑制期。免疫抑制阶段失调是败血症相关死亡的主要原因。败血症所致的免疫抑制和机能失调是败血症相关死亡的主要原因,因此在这一阶段进行的抗炎治疗将是有害的。这表明关于个体化免疫应答的进一步信息将有助于启动诸如抗IL6的疗法,并且在整个治疗过程中监测促炎和抗炎反应将是有价值的。另外,已知败血症的定义和反应在儿童和新生儿中是不同的,因此,有几个原因导致儿童感染COVID-19可能会更容易好。另外,进一步了解不同年龄组的免疫反应差异对于靶向免疫疗法也很有价值。 4.附件: 原文链接: https://www.nature.com/articles/s41390-020-0881-y_reference.pdf
  • 《Nature,4月21日,The potential danger of suboptimal antibody responses in COVID-19》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-04-22
    • The potential danger of suboptimal antibody responses in COVID-19 Akiko Iwasaki & Yexin Yang Nature Reviews Immunology (2020) There is a desperate need for effective therapies and vaccines for SARS-CoV-2 to mitigate the growing economic crisis that has ensued from societal lockdown. Vaccines are being developed at an unprecedented speed and are already in clinical trials, without preclinical testing for safety and efficacy. Yet, safety evaluation of candidate vaccines must not be overlooked.